The death rate in the group treated with daraxonrasib was 60% lower than those on chemotherapy. This is hailed as a major advance against metastatic pancreatic cancer.
Joshua Cohen is an independent healthcare analyst at various esteemed publications. He specializes in healthcare policy, drug pricing, and reimbursement, with a focus on consumer health and public health issues. His insights and analyses have been featured in notable outlets including Salon Media Group, Inc., The New Yorker, and Forbes.














